The regulation of cell and gene therapy products (CGTPs) is essential for ensuring their safety, efficacy, and timely access to the market. This article describes Malaysia’s current regulatory framework for CGTPs, emphasizing available pathways such as priority review, conditional registration, facilitated registration, and orphan drug designation. Additionally, this study employs a comparative analysis to examine expedited regulatory pathways and orphan drug designations in the United States (US), European Union (EU), and Japan, highlighting key differences that impact CGTP approvals. Notably, Malaysia utilizes a broader regulatory approach, similar to the EU’s Priority Medicines, in contrast to the US and Japan, which have specific pathways, such as Regenerative Medicine Advanced Therapy and the conditional and time-limited designation, respectively. The facilitated registration pathway introduced in Malaysia is unique among the reviewed jurisdictions. It relies on foreign regulatory assessments and subsequently accelerates market access in Malaysia. The study concludes that product registration holders can utilize existing regulatory pathways in Malaysia to expedite CGTP approvals. Furthermore, adopting a tailored regulatory framework similar to those in other regions could enhance Malaysia’s ability to support the development and commercialization of CGTPs, ultimately improving both patient safety and access to these innovative treatments.
1. Iglesias-Lopez C. The life of advanced therapies: from academia to prescription. 2023.
2. Maruyama Y. Regulatory update of regenerative medicine in Japan [Internet]. 2024. Available from: https://www.pmda.go.jp/english/review-services/reviews/0003.html
3. Goula A, Gkioka V, Michalopoulos E, Katsimpoulas M, Noutsias M, Sarri EF, et al. Advanced therapy medicinal products challenges and perspectives in regenerative medicine [Internet]. J Clin Med Res. 2020;12:780–6. Available from: www.jocmr.org
4. Yoon J, Lee S, Kim MJ, Kim JH. Brief summary of the regulatory frameworks of regenerative medicine therapies. Front Pharmacol. 2024;15:1–7. doi: https://doi.org/10.3389/fphar.2024.1486812
5. Sato Y, Ono S. Regulatory environment and approvals in cell and gene therapy products between Japan, the USA, and the EU [Internet]. Ther Innov Regul Sci Internet. 2023;57(2):227–37. doi: https://doi.org/10.1007/s43441-022-00455-4
6. Foo JB, Looi QH, Chong PP, Hassan NH, Yeo GEC, Ng CY, et al. Comparing the therapeutic potential of stem cells and their secretory products in regenerative medicine. Stem Cells Int. 2021; 2021:30. doi: https://doi.org/10.1155/2021/2616807
7. Ciccocioppo R, Comoli P, Astori G, Del Bufalo F, Prapa M, Dominici M, et al. Developing cell therapies as drug products. Br J Pharmacol. 2021;178(2):262–79. doi: https://doi.org/10.1111/bph.15305
8. Perez C, Gruber I, Arber C. Off-the-shelf allogeneic T Cell therapies for cancer: opportunities and challenges using naturally occurring “universal” donor T cells. Front Immunol. 2020;11:1–6. doi: https://doi.org/10.3389/fimmu.2020.583716
9. Ancans J.Cell therapy medicinal product regulatory framework in europe and its application for MSC-based therapy development. Front Immunol. 2012;3:1–8. doi: https://doi.org/10.3389/fimmu.2012.00253
10. Lee S, Lee JH. Cell and gene therapy regulatory, pricing, and reimbursement framework: with a focus on South Korea and the EU. Front Public Health. 2023;11:3–4. doi: https://doi.org/10.3389/fpubh.2023.1109873
11. Drago D, Foss-Campbell B, Wonnacott K, Barrett D, Ndu A. Global regulatory progress in delivering on the promise of gene therapies for unmet medical needs [Internet]. Mol Ther Methods Clin Dev. 2021;21:524–9. doi: https://doi.org/10.1016/j.omtm.2021.04.001
12. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Directive for the enforcement of Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs), December 2015 dan Good Tissue Practice Guideline, 2nd edition, December 2015 [Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index. php/en/directive-general/100-directives-biologics/1171-direktif-untuk-menguatkuasakan-penggunaan-guidance-document-and-guidelines-for-registration-of-cell-and-gene-therapy-products-cgtps-december-2015-dan-good-tissue-practice-guideline-2nd-edition-december-2015.html
13. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Guidance Document and Guidelines for Registration of Cell and Gene Therapy Products (CGTPs) in Malaysia [Internet]. Petaling Jaya (MY): NPRA; 2022 Feb 22 [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/guideline-bio/1527314-guidance-document-and-guidelines-for-registration-of-cell-and-gene-therapy-products-cgtps-in-malaysia-2.html
14. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Directive regarding the Implementation of product registration and enforcement of cell and gene therapy products (CGTPs) in stages as well as the addition of list of products outside the scope of CGTPs by the DCA [Internet]. Petaling Jaya (MY): NPRA; 2020 Dec 15 [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/directive-general/1527171-direktif-berkenaan-pelaksanaan-pendaftaran-produk-dan-penguatkuasaan-secara-berperingkat-bagi-produk-terapi-sel-dan-gen-cgtps-serta-tambahan-senarai-produk-di-luar-skop-kawalan-cgtps-oleh-pbkd.html
15. Arcidiacono J.International harmonization for cell and gene therapy products. Adv Exp Med Biol. 2023;1430:235–40. doi: https://doi.org/10.1007/978-3-031-34567-8_14
16. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Drug Registration Guidance Documents (DRGD) E-Book [Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/drug-registration-guidance-documents-drgd-e-book.html
17. Iglesias-Lopez C, Obach M, Vallano A, Agustí A. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States [Internet]. Cytotherapy Internet. 2021;23(3):261–74. Available from: https://consensus.app/papers/comparison-pathways-approval-advanced-therapiesiglesiaslopez/e563b429e71854f1a48e0ca01703c05c/
18. Qiu T, Pochopien M, Liang S, Saal G, Paterak E, Janik J, et al. Gene therapy evidence generation and economic analysis: pragmatic considerations to facilitate fit-for-purpose health technology assessment. Front Public Health. 2022;10:1–9. doi: https://doi.org/10.3389/fpubh.2022.773629
19. Legislation Malaysia. Sales of Drugs Act 1952 (Act 368) [Internet] [cited 2025 Sep 26]. Available from: https://pharmacy.moh.gov.my/sites/default/files/document-upload/sales-drug-act-1952-act-368.pdf
20. Legislation Malaysia. Control of Drugs and Cosmetics Regulations 1984 (PU(A) 223/1984) [Internet] [cited 2025 Sep 26]. Available from: https://pharmacy.moh.gov.my/sites/default/files/document-upload/control-drugs-and-cosmetics-regulation-1984.pdf
21. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Malaysian guideline for application of Clinial Trial Import License and Clinical Trial Exemption[Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/guideline-for-the-submission-of-product-samples-for-laboratory-testing/clinical-trial/clinical-trial-guidelines.html
22. Abas A, Khoo YSK. Regulation of biologicals in Malaysia. GaBI J.2014;3(4):193–8. doi: https://doi.org/10.5639/gabij.2014.0304.044
23. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. ASEAN guidance documents [Internet] [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/asean-guidance-documents.html
24. European Medicines Agency. ICH M4 Common Technical Document (CTD) for the Registration of Pharmaceuticals for Human Use: Organisation of the Common Technical Document (Scientific Guideline) [Internet]. Amsterdam (NL): EMA; [cited 2025 Sep 26]. Available from: https://www.ema.europa.eu/en/ich-m4-common-technical-document-ctd-registration-pharmaceuticals-human-use-organisation-ctd-scientific-guideline
25. Loh EYX, Ab Ghani A, Ahmad R. Regulatory oversight of cell and gene therapy products in Malaysia [Internet]. Adv Exp Med Biol. 2023;1430:181–95. Available from: https://pubmed.ncbi.nlm.nih.gov/37526848/
26. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia.Technical Evaluation Summary: Zolgensma [Internet] [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/17050/pharma/555276/1709804622. pdf
27. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Zolgensma approval information [Internet]. Tokyo (JP): PMDA; [cited 2025 Sep 26]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html
28. U.S. Food and Drug Administration. FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease [Internet]. Silver Spring (MD): FDA; 2019 May 24 [cited 2025 Sep 26]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease
29. European Medicines Agency. Zolgensma: EPAR -product information [Internet]. Amsterdam (NL): EMA; [cited 2025 Sep 26]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma
30. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Facilitated registration pathway guideline (PDF attachment) [Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/17050/pharma/555276/1709804622.pdf
31. National Pharmaceutical Regulatory Agency (NPRA), Malaysia. Guidelines on conditional registration for new chemical entities and biologics in Malaysia. 2nd ed. December 2020 [Internet]. Petaling Jaya (MY): NPRA; 2020 Dec [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/guideline-bio/1527353-guidelines-on-conditional-registration-for-new-chemical-entities-and-biologics-in-malaysia-2nd-edition-december-2020.html
32. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Good Laboratory Practice (GLP) Requirements for Non-Clinical Safety Studies for New Chemical Entity (NCE), biologics and herbal products with high therapeutic claim [Internet]. Petaling Jaya (MY): NPRA; 2016 Jul [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/images/CircularsDirective/RegulatoryInformation/2016/160701DIREKTIFBIL92016.pdf
33. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. DRGD Appendix 12: Priority Review [Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/easyarticles/images/users/1153/drgd_appendices/APPENDIX-12-Priority-Review.pdf
34. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia.Technical Evaluation Summary: Besremi [Internet] [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/99412/pharma/555595/1721873214.pdf
35. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Direktif on the use of Guidelines on Conditional Registration for New Chemical Entities and Biologics [Internet]. Petaling Jaya (MY): NPRA; 2021 [cited 2025 Sep 27]. Available from: https://www.npra.gov.my/index.php/en/directive-general/100-directives-biologics/1510-direktif-untuk-melaksanakan-guidelines-on-conditional-registration-for-new-chemical-entities-and-biologics-2.html
36. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Technical Evaluation Summary: Lunsumio [Internet]. Petaling Jaya (MY): NPRA; 2019 [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/569/pharma/555945/1731996905.pdf
37. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Directive Bil 7/2019: Directive on the use of Guidelines on Facilitated Registration Pathway: Abbreviated and Verification Review [Internet]. Petaling Jaya (MY): NPRA; 2019 [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/easyarticles/images/users/1048/gambar/DirektifBil72019.pdf
38. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Directive regarding the updated version and the use of Guideline for Facilitated Registration Pathway (FRP), Revision 1, 2023 [Internet]. Petaling Jaya (MY): NPRA; 2023 Nov 16 [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/en/directive-general/1527544-direktif-berkenaan-pengemaskinian-dan-pelaksanaan-guideline-for-facilitated-registration-pathway-frp-revision-1-2023.html
39. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Registration application submitted via facilitated registration pathway (FRP): FAQ [Internet]. Petaling Jaya (MY): NPRA; 2024 [cited 2025 Sep 26]. Available from: https://npra.gov.my/index.php/en/nce-guidelines/453-english/announcement-main/announcement-2024/1527630-registration-application-submitted-via-facilitated-registration-pathway-frp-faq.html
40. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Technical Evaluation Summary: Kauliv [Internet]. Petaling Jaya (MY): NPRA; 2024 Dec [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/17051/pharma/559391/1728433376.pdf
41. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Technical Evaluation Summary: Vyepti [Internet]. Petaling Jaya (MY): NPRA; 2024 Dec [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/45476/pharma/556446/1725850115.pdf
42. National Pharmaceutical Regulatory Agency (NPRA) Ministry of Health Malaysia. Technical Evaluation Summary for Facilitated Registration Pathway (FRP): Arexvy. 2024;2024:1–11. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/724/pharma/562114/1725331846.pdf
43. National Pharmaceutical Regulatory Agency, Ministry of Health Malaysia. Technical Evaluation Summary for Yuflyma [Internet]. May 2024. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/36102/pharma/559234/1724637302.1ml%20 Solution%20for%20Injection%20in%20pre-filled%20pen_ DCA%20396_May2024.pdf
44. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Technical Evaluation Summary: Yesafili [Internet]. Petaling Jaya (MY): NPRA; 2024 Dec [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/38316/pharma/562889/Yesafili_DCA 403_Dec 2024.pdf
45. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Technical Evaluation Summary: Ultomiris [Internet]. Petaling Jaya (MY): NPRA; 2024 Dec [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/668/pharma/558382/1730787435.pdf
46. Ministry of Health Malaysia. Malaysian orphan medicines guideline 2020 [Internet]. Putrajaya (MY): Pharmaceutical Services Programme, Ministry of Health Malaysia; 2020 [cited 2025 Sep 26]. Available from: https://pharmacy.moh.gov.my/en/documents/malaysian-orphan-medicines-guideline-2020.html
47. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Appendix 13: Designation and registration of orphan medicines (DRGD Appendices) [Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/easyarticles/images/users/1153/drgd_appendices/APPENDIX-13-Designation-and-Registration-of-Orphan-Medicines.pdf
48. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Orphan medicines approved [Internet]. Petaling Jaya (MY): NPRA; [cited 2025 Sep 26]. Available from: https://www.npra.gov.my/index.php/my/informationen/new-products-indication/orphan-medicines-approved.html
49. National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia. Technical Evaluation Summary: Soliris [Internet]. Petaling Jaya (MY): NPRA; 2024 Dec [cited 2025 Sep 26]. Available from: https://quest3plus.bpfk.gov.my/front-end/attachment/668/pharma/561178/1729481330.pdf
50. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions -Drugs and Biologics [Internet]. Silver Spring (MD): FDA; May 2014. 40 p. [cited 2025 Sep 27]. Available from: https://www.fda.gov/media/86377/download
51. U.S. Food and Drug Administration. Expedited programs for regenerative medicine therapies for serious conditions: draft guidance for industry [Internet]. Silver Spring (MD): FDA; September 2025 [cited 2025 Sep 27]. Available from: Expedited Programs for Regenerative Medicine Therapies for Serious Conditions | FDA
52. European Medicines Agency. Guidance for applicants seeking access to PRIME scheme [Internet]. Amsterdam (NL): EMA; 2024 Oct 03. Report No.: EMA/7872/2021. [cited 2025 Sep 27]. Available from: https://www.ema.europa.eu/en/documents/other/european-medicines-agency-guidance-applicants-seeking-access-prime-schemeen.pdf
53. European Medicines Agency. Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to Article 14(9) of Regulation (EC) No 726/2004 [Internet]. Amsterdam (NL): EMA; 2016 Feb 25. Report No.: EMA/CHMP/671361/2015 Rev. 1 [cited 2025 Sep 27]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-scientific-application-and-practical-arrangements-necessary-implement-procedure-
54. Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K, et al. Achievements and challenges of the Sakigake designation system in Japan. Br J Clin Pharmacol. 2021;87(10):4027–35. doi: https://doi.org/10.1111/bcp.14807
55. Ministry of Health Labor and Welfare (MHLW) Japan. Strategy of SAKIGAKE-the Ministry of Health, Labour and Welfare. 2014;20. Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/140729-01.html
56. Ministry of Health Labor and Welfare (MHLW) Japan. Strategy of SAKIGAKE as a package. 2018; Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/140729-01-02.pdf
57. European Medicines Agency. Orphan designation overview [Internet]. Amsterdam (NL): EMA; [cited 2025 Sep 27]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
58. European Medicines Agency. Rare diseases, orphan medicines: getting the facts straight [Internet]. London (UK): EMA; 2018 Feb 28. Report No.: EMA/551338/2017. [cited 2025 Sep 27]. Available from: https://www.ema.europa.eu/en/documents/other/rare-diseases-orphan-medicines-getting-facts-straighten.pdf
59. U.S. Food and Drug Administration, Office of Orphan Products Development. Recommended tips for creating an orphan drug designation application: webinar slides [Internet]. Silver Spring (MD): FDA; 2018 [cited 2025 Sep 27]. Available from: https://www.fda.gov/media/111762/download
60. Ministry of Health Labor and Welfare (MHLW) Japan. Overview of Orphan Drug/Medical Device Designation System [Internet]. 2009 [cited 2025 Feb 18]. Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphandrug.html
61. Maruyama Y. Regulatory aspects of cell and gene therapy products: the PMDA perspective. 2024;1430:155–79. Available from: https://www.pmda.go.jp/english/review-services/reviews/0003.html
62. EMA. Guideline on the scientific application and the practical arrangements necessary to implement commission Regulation (EC) No 507/2006 on the conditional marketing authorization for medicinal products for human use falling within the scope of Regulation (EC. EMA [Internet]. 2006;44:1–10. Available from: www.ema.europa.eu/docs/enGB/...guideline/.../WC500004908.pdf
63. Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan [Internet]. Int J Mol Sci. 2019;20:3801. Available from: https://consensus.app/papers/expedited-regulatory-review-processes-innovative-nagai/22d3af9a532c5b1496af449f22389b9a/
64. U.S. Food and Drug Administration, Office of Orphan Products Development. Orphan drug designation webinar script: tips for submitting an orphan drug designation application [Internet]. Silver Spring (MD): FDA; 2018 [cited 2025 Sep 26]. Available from: https://www.fda.gov/media/111762/download
65. European Medicines Agency. Rare diseases, orphan medicines: getting the facts straight. European Medicines Agency [Internet]. 2018;44:5–8. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/orphan-designation-overview
66. Domike R, Raju GK, Sullivan J, Kennedy A. Expediting treatments in the 21st century: orphan drugs and accelerated approvals [Internet]. Orphanet J Rare Dis. 2024;19(1):418. doi: https://doi.org/10.1186/s13023-024-03398-1
67. U.S. Food and Drug Administration, Department of Health and Human Services. Electronic Code of Federal Regulations. Title 21, Chapter I, Subchapter D, Part 316: Orphan Drugs [Internet]. Washington (DC): U.S. Government Publishing Office; [cited 2025 Sep 26]. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-316
68. Ministry of Health, Labour and Welfare (MHLW), Japan. Orphan Drug and Medical Device Designation System. Ministry of Health, Labour and Welfare (MHLW) [Internet]. Tokyo (Japan): Ministry of Health, Labour and Welfare (MHLW); [updated 2024]. [cited 2025 Sep 26]. Available from: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphandrug.html
69. National Pharmaceutical Regulatory Agency (NPRA). Guidance document for pre-submission meeting (PSM). 2020;21. Available from: https://www.npra.gov.my/easyarticles/images/users/1048/gambar/Pekelililing-PSM_guidance.pdf
70. Kwok M, Foster T, Steinberg M. Expedited programs for serious conditions: an update on breakthrough therapy designation [Internet]. Clin Ther Internet. 2015;37(9):2104–20. doi: https://doi.org/10.1016/j.clinthera.2015.07.011
71. Kajiwara E, Shikano M. Considerations and regulatory challenges for innovative medicines in expedited approval programs: breakthrough therapy and sakigake designation. Ther Innov Regul Sci. 2020;54(4):814–20. doi: https://doi.org/10.1007/s43441-019-00019-z
72. Cai Y, Sui L, Wang J, Qian W, Peng Y, Gong L, et al. Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study [Internet]. BMC Med Internet. 2024;22(1):421. doi: https://doi.org/10.1186/s12916-024-03637-z
73. Sharma R, Gulati A, Chopra K. Era of surrogate endpoints and accelerated approvals: a comprehensive review on applicability, uncertainties, and challenges from regulatory, payer, and patient perspectives [Internet]. Eur J Clin Pharmacol. 2025;81(5):605–23. doi: https://doi.org/10.1007/s00228-025-03822-w
74. Noda S, Kobayashi Y, Okura N, Shinohara K, Asano J, Matsumoto J.Regulatory advancements in Japan’s conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of the first conditional and time-limited approved cellula [Internet]. Cytotherapy Internet. 2025;00000: doi: https://doi.org/10.1016/j.jcyt.2025.02.010
75. Lee NK, Chang JW. Manufacturing cell and gene therapies: challenges in clinical translation. Ann Lab Med. 2024;44(4):314–23. doi: https://doi.org/10.3343/alm.2023.0382
76. Franco P, Jain R, Rosenkrands-Lange E, Hey C, Koban MU. Regulatory pathways supporting expedited drug development and approval in ICH member countries [Internet]. Ther Innov Regul Sci. 2023;57(3):484–514. doi: https://doi.org/10.1007/s43441-022-00480-3
77. Tan EHP, Chinchalongporn V, Dumadi F, Tsurumaki Y, Jung MH, Kellathur SN, et al. Pursuing cell therapy approvals in APAC: your guide to navigating regulations in Japan, South Korea, and Singapore [Internet]. Cytotherapy Internet. 2025;00000: doi: https://doi.org/10.1016/j.jcyt.2025.03.504
78. Feng K, Miranda AV, Obnial JC, Ebhodaghe ID, Lucero-Prisno DE. Drug regulatory harmonization in the Association of Southeast Asian Nations: is it time for an ASEAN medicines agency? A policy review [Internet]. Clin Epidemiol Glob Health. 2024;28:101649. doi: https://doi.org/10.1016/j.cegh.2024.101649
79. Hata T, Nakamura K, Yonemori K, Noguchi E, Watanabe M, Sohn J, et al. Regulatory and operational challenges in conducting Asian International Academic Trial for expanding the indications of cancer drugs. Clin Transl Sci. 2021;14(3):1015–25.
80. Rouce RH, Grilley BJ.How to democratize cell and gene therapy: a global approach [Internet]. Mol Therapy. 2025;33(5):2082–90. Available from:https://www-sciencedirect-com.uitm.idm.oclc.org/science/article/abs/pii/S1525001625002709?via%3Dihub
81. Lysaght T, Munsie M, Castricum ADAM, Hui JHP, Okada K, sato YOJI, et al. A roundtable on responsible innovation with autologous stem cells in Australia, Japan and Singapore [Internet]. Cytotherapy Internet. 2018;20(9):1103–09. doi: https://doi.org/10.1016/j.jcyt.2018.06.004
82. Imran SAM, M. Hamizul MHA, Khairul Bariah AAN, Wan Kamarul Zaman WS, Nordin F. Regenerative medicine therapy in Malaysia: an update. Front Bioengineering Biotechnol. 2022;10:1–15. doi: https://doi.org/10.3389/fbioe.2022.789644
83. Shi J, Chen X, Hu H, Oi C, Ung L. The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the WHO Global Benchmarking Tool standards. J Pre-proof. 2024;2024:954–66. doi: https://doi.org/10.1016/j.jcyt
Year
Month